Royalty Pharma plc

RPRX - CIK 0001802768

Market cap$21.16 B

Rank#600

SEC filings588

Royalty Pharma plc trades as RPRX and has a market capitalization of $21.16 B, making it the #600 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.38B, up 5.1% from the prior year and net income of $770.95M. This page tracks Royalty Pharma plc through 588 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$2.38BFY 2025

Net income (latest FY)$770.95MFY 2025

Operating cash flow (latest FY)$2.49BFY 2025

Total assets (latest FY)$19.62BFY 2025

Net margin32.4%latest FY

Financial performance

Over the last 7 fiscal years Royalty Pharma plc's revenue grew from $1.79B to $2.38B, a compound annual growth rate of 4.1%. Net profit margin compressed from 76.8% to 32.4% over the same period - every figure below comes from the company's audited annual filings.

RPRX annual revenueView details

Key statistics

Market cap: $21.16 B
P/E ratio (trailing FY): 27.4
EPS (diluted)FY 2025: $1.78
Long-term debtas of 2026-03-31: $8.96B
Cash & equivalentsas of 2026-03-31: $586.39M
Stock buybacksFY 2025: $1.23B
Current ratioas of 2026-03-31: 2.66
R&D expenseFY 2025: $452.00M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-21
Insider sale notice	144	2026-05-20
Insider trade	4	2026-05-15
Insider trade	4	2026-05-15
Insider sale notice	144	2026-05-14
Insider sale notice	144	2026-05-14
13F-NT	-	2026-05-14
SCHEDULE 13G/A	-	2026-05-14

Browse the full filing history (588 filings)

Recent press releases

Royalty Pharma reports first quarter 2026 results | Royalty Pharma2026-05-06
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 | Royalty Pharma2026-05-06
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation | Royalty Pharma2026-04-21
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
Royalty Pharma Declares Second Quarter 2026 Dividend | Royalty Pharma2026-04-17
Royalty Pharma Declares Second Quarter 2026 Dividend
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases | Royalty Pharma2026-03-30
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Similar companies

The largest companies sharing Royalty Pharma plc's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T RPRX vs LLY

JNJJohnson & Johnson$573.98 B RPRX vs JNJ

ABBVAbbVie Inc.$399.47 B RPRX vs ABBV

MRKMerck & Co., Inc.$293.16 B RPRX vs MRK

AZNAstraZeneca PLC$286.27 B RPRX vs AZN

Frequently asked questions

What is Royalty Pharma plc's market cap?

Royalty Pharma plc (RPRX) has a market capitalization of $21.16 B as of 2026-06-10, ranking #600 among US-listed companies.

How much revenue does Royalty Pharma plc make?

Royalty Pharma plc reported revenue of $2.38B for fiscal year 2025, an increase of 5.1% year over year.

Is Royalty Pharma plc profitable?

Yes. Royalty Pharma plc reported net income of $770.95M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.